Aug 28, 2008 / Comment Letters

MedPAC comment on CMS’s proposed rule entitled: Medicare Program; Revisions to payment policies under the physician fee schedule and other revisions to Part B for CY 2009; and …

Research Areas:

Physicians And Other Health Professionals

Oct 16, 2007 / Contractor Reports

Coverage and Pricing of Drugs That Can Be Covered Under Part B and Part D

Research Areas:

Beneficiaries and Coverage, Drugs, Devices, and Tests

Aug 30, 2007 / Comment Letters

MedPAC comment on CMS’s proposed rule entitled: Medicare program; Revisions to payment policies under the physician fee schedule, and other Part B payment policies for CY 2008

Research Areas:

Physicians And Other Health Professionals, Regional Issues

Jun 01, 2007 / Chapters

Chapter 7: Issues in Medicare coverage of drugs (June 2007 report)

Research Areas:

Drugs, Devices, and Tests, Private Plans

Oct 11, 2006 / Comment Letters

MedPAC comment on CMS’s proposed rule entitled: Medicare program; Revisions to payment policies under the physician fee schedule for calendar year 2007 and other changes to payment under Part B

Research Areas:

Ambulatory Care Settings, Physicians And Other Health Professionals

Jul 12, 2006 / Congressional Testimony

Testimony: Medicare Part B drugs and oncology

Research Areas:

Ambulatory Care Settings, Drugs, Devices, and Tests

Mar 17, 2006 / Contractor Reports

Access to Chemotherapy Services for Medicare Beneficiaries: Summary of Focus Groups with Beneficiaries

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage

Sep 16, 2005 / Comment Letters

MedPAC comment on CMS’s proposed rule entitled: Proposed Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates

Research Areas:

Ambulatory Care Settings, Hospitals

Dec 30, 2004 / Reports

December 2004 Report to the Congress: Benefit Design and Cost Sharing in Medicare Advantage Plans

Research Areas:

Hospitals, Physicians And Other Health Professionals

Oct 15, 2003 / Comment Letters

MedPAC comment on CMS’s notice of proposed rulemaking entitled: Medicare Program: Payment Reform for Part B Drugs

Research Areas:

Drugs, Devices, and Tests